about
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancerAmplification of EIF3S3 gene is associated with advanced stage in prostate cancerThe mutational landscape of prostate cancerIdentification of novel transcription factor-like gene from human intestinal cellsRAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancerExpression of androgen receptor coregulators in prostate cancerPrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancerChk1 targeting reactivates PP2A tumor suppressor activity in cancer cellsConstruction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression dataAndrogen regulation of the androgen receptor coregulators.Somatic mutation analysis of MYH11 in breast and prostate cancerClinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H.Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerLoss of PTEN is associated with aggressive behavior in ERG-positive prostate cancerOverall and worst gleason scores are equally good predictors of prostate cancer progression.Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays.DOT1L-HES6 fusion drives androgen independent growth in prostate cancerGeneration of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.Origins and functional consequences of somatic mitochondrial DNA mutations in human cancerMapping of the chromosomal amplification 1p21-22 in bladder cancer.Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.The evolutionary history of lethal metastatic prostate cancer.The molecular genetics of prostate cancer.Role of the chromobox protein CBX7 in lymphomagenesis.Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Alterations of androgen receptor in prostate cancer.Epigenetically altered miR-193b targets cyclin D1 in prostate cancerC/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer.CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections.Stat3 promotes metastatic progression of prostate cancer.Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.
P50
Q24645931-760514A5-9812-4C54-84E8-FDD9FCD00D33Q24685619-A7EC3416-8D4D-4631-8BCE-977980F3F44FQ26851631-64E8B0DF-35B5-4691-B59A-16310FA1E8D4Q28140819-AEBDC09A-039E-4F1D-BDC6-BA8E3F62B9ABQ28182316-647CFC17-891C-4085-9DB8-149679D3ECBEQ28244019-B0E66D61-E5C8-4F8B-9265-8849E712883EQ28248025-C383C7F0-1524-4BB0-A011-0775DD2C1D70Q28299365-ACEFF11B-A345-4BE1-B792-C3826953253DQ30982222-3D231B89-2E8A-488B-B608-F67EACDF3C7BQ33357016-070048BD-69C0-4152-9B97-B2B61B3A4096Q33369984-C1635F40-F29B-42FE-9E0D-1AF13426DAE5Q33634701-4853A97B-3554-48C4-934E-9E230213C5FDQ33640983-2EB705D0-17D2-4DFA-8028-EBC2FB5F59B2Q33700619-2310118C-1C57-4E5C-BD34-D4B09069DB30Q33730189-97F53E23-78E2-428D-81EF-D9003FBE6823Q33862890-C0EA1B8E-57DB-4189-A9D7-47B428CC1090Q34042039-965EA316-5B88-473F-880C-AA986D0A7A00Q34058710-6FF1DCC2-1822-4F8B-B06F-7D73E49C8758Q34127887-5F8E20C9-8E11-4FD1-A47F-BC885C85FE87Q34342466-8EFD470C-87F9-44CA-9EC1-756207D1A39AQ34830129-4C4B7B1B-561A-425F-B4D9-978D77C4AE1FQ35212322-939C3A2F-4EE0-4946-B318-607F27691F72Q35227493-1DD6DACD-A0B6-4077-96E3-603CB6C4A440Q35234637-D005741E-0591-4261-9505-040319C36554Q35248192-BEC57573-7D55-4EA6-8D81-D766E579853FQ35548366-20B904A6-95AC-4031-9882-7DED1642747CQ35579585-A2AE2499-EEAD-47E6-9E43-617024549F37Q35690238-C6F04B97-175F-4EBD-8A26-7199E62803E1Q35742514-BA874095-FE12-4DF2-A774-B46C0EB3BA30Q35787051-D06BA58F-E5F3-45B2-B8C7-F61017E59B44Q35944835-6FC60479-D458-4D45-80C7-05B9D08532DDQ36017026-5E537ED5-C5F2-443B-99FF-20EC5250803AQ36051801-A36F7077-A48E-4361-BF7F-1CB453576610Q36232068-9807668B-2B20-438D-A11C-6C96387251FFQ36260616-513DDA46-CA87-4899-982D-A0B75A7A40A0Q36497254-6EC3E345-B4AB-4375-A8D1-3CF1F78A4C33Q36580474-AB0FCFD7-1B10-4DCE-8A51-E1D028CF849EQ36606721-6A2114F3-FA0A-49D7-9621-7182ECAA03EAQ36691140-B3D86991-5410-49C6-A685-4BF1A0E9E29DQ36859396-198730D6-942F-492F-B189-21FCEE6923EC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tapio Visakorpi
@ast
Tapio Visakorpi
@en
Tapio Visakorpi
@es
Tapio Visakorpi
@fr
Tapio Visakorpi
@nl
Tapio Visakorpi
@pt
Tapio Visakorpi
@sl
type
label
Tapio Visakorpi
@ast
Tapio Visakorpi
@en
Tapio Visakorpi
@es
Tapio Visakorpi
@fr
Tapio Visakorpi
@nl
Tapio Visakorpi
@pt
Tapio Visakorpi
@sl
prefLabel
Tapio Visakorpi
@ast
Tapio Visakorpi
@en
Tapio Visakorpi
@es
Tapio Visakorpi
@fr
Tapio Visakorpi
@nl
Tapio Visakorpi
@pt
Tapio Visakorpi
@sl
P106
P31
P496
0000-0002-5004-0364